Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes plc Reports Third Quarter 2026 Financial Results

Tuesday, November 3, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alkermes plc reported its financial results for the third quarter of 2026. The earnings press release and presentation are available on the company's investor relations website. A conference call and webcast are scheduled for today at 8:00 a.m. ET to discuss these results and provide further updates.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes reported financial results for Q3 2026.
  • The company will provide an update during the conference call.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+33%
120-day peak, hindsight
Typical move
3.1%
average across 10 past catalysts
Lead asset
ALKS 7290
Phase 2 · Attention Deficit Disorder With Hyperactivity (ADHD)

Full Press Release Details

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) today, to discuss these financial results and provide an update on the company. The webcast may be accessed

Frequently Asked Questions

When did Alkermes report its Q3 2026 results?

Alkermes reported its Q3 2026 results on September 30, 2026.

Where can I find the earnings press release?

The earnings press release is available on Alkermes' investor relations website.

What time is the conference call for Q3 results?

The conference call is scheduled for 8:00 a.m. ET today.

What will be discussed during the conference call?

The call will discuss the financial results and provide company updates.

ShareAdd on Google
Tags: ALKS Alkermes Q3 2026 financial results earnings conference call
Last updated: Nov 3, 2026

Biotech snapshot

Cash runway
$691M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALKS 7290Phase 2
Attention Deficit Disorder With Hyperactivity (ADHD) →

Catalyst track record

+33%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →